Recruiting
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment - CA028-001
Updated: 30 January, 2019 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Participants must have an ECOG performance status of less than or equal to 1 - Participants must have had prior therapy - Participants must have at least 2 lesions with measurable disease as defined by RECIST Version 1.1 Exclusion Criteria: - Participants must not have suspected, known, or progressive CNS metastases, have untreated CNS metastases, or have the CNS as the only site of disease - Participants must not have carcinomatous meningitis - Participants must not have other active malignancy requiring concurrent intervention Other protocol defined inclusion/exclusion criteria could apply
